Seminars in Interventional Radiology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy
Semin intervent Radiol 2020; 37: 499-507 DOI: 10.1055/s-0040-1720951Neuroendocrine tumor liver metastases are treated by a multidisciplinary cohort of physicians that work together to achieve optimal clinical results for their patients. This review addresses critical concepts in diagnosis and workup of such patients followed by medical, surgical, and liver-directed arterial and ablative therapies. Specific perioperative care for these patients is crucial in avoiding dreaded complications related to Carcinoid Crisis. The recent introduction of Peptide Receptor Radionuclide Therapy as a therapeutic option has impacted some o...
Source: Seminars in Interventional Radiology - December 11, 2020 Category: Radiology Authors: Lehrman, Evan D. Fidelman, Nicholas Tags: Review Article Source Type: research
Interventional Treatment of Hepatic Metastases from Colorectal Cancer
Semin intervent Radiol 2020; 37: 492-498 DOI: 10.1055/s-0040-171919Modern systemic therapies provide a significant survival benefit in metastatic colorectal cancer. Despite these advances, the durability of response remains limited and nearly all patients progress on systemic treatment. Colorectal liver metastases (CLM) develop in approximately half of patients with metastatic disease and contribute to mortality in most patients. In selected patients, surgical resection of hepatic metastases prolongs survival, indicating the benefits of the targeted treatment of CLM through alternate means. Minimally invasive interventiona...
Source: Seminars in Interventional Radiology - December 11, 2020 Category: Radiology Authors: Sutphin, Patrick D. Ganguli, Suvranu Tags: Review Article Source Type: research
Interventional Oncology Approach to Hepatic Metastases
Semin intervent Radiol 2020; 37: 484-491 DOI: 10.1055/s-0040-1719189Metastatic liver disease is one of the major causes of cancer-related morbidity and mortality. Locoregional therapies offered by interventional oncologists alleviate cancer-related morbidity and in some cases improve survival. Locoregional therapies are often palliative in nature but occasionally can be used with curative intent. This review will discuss important factors to consider prior to palliative and curative intent treatment of metastatic liver disease with locoregional therapy. These factors include those specific to the tumor, liver function, liv...
Source: Seminars in Interventional Radiology - December 11, 2020 Category: Radiology Authors: O'Leary, Cathal Soulen, Michael C. Shamimi-Noori, Susan Tags: Review Article Source Type: research
Intrahepatic Cholangiocarcinoma
Semin intervent Radiol 2020; 37: 475-483 DOI: 10.1055/s-0040-1719188Cholangiocarcinoma is the second most common primary malignancy of the liver. This review will focus on the mass-forming intrahepatic type of this disease and discuss the role of medical, surgical, and radiation oncology in managing this difficult disease. A global understanding to the management of intrahepatic cholangiocarcinoma (ICC) can help the interventional radiologist understand the role of locoregional therapies such as ablation, transarterial chemoembolization, and radioembolization in the management of ICC. [...] Thieme Medical Publishers, Inc. ...
Source: Seminars in Interventional Radiology - December 11, 2020 Category: Radiology Authors: Entezari, Pouya Riaz, Ahsun Tags: Review Article Source Type: research
Therapy in Advanced Hepatocellular Carcinoma
Semin intervent Radiol 2020; 37: 466-474 DOI: 10.1055/s-0040-1719187Treatment of advanced hepatocellular carcinoma (HCC) is challenging. Several randomized clinical trials are investigating the efficacy of systemic therapy, immunotherapy, and locoregional therapy as monotherapy or combined with other modalities in the treatment of HCC. Systemic therapy is the preferred treatment in advanced disease. To date, multiple first-line and second-line agents received Food and Drug Administration approval. For over a decade, sorafenib was the only first-line agent. In May 2020, combination of atezolizumab and bevacizumab has been a...
Source: Seminars in Interventional Radiology - December 11, 2020 Category: Radiology Authors: Javan, Hanna Dayyani, Farshid Abi-Jaoudeh, Nadine Tags: Review Article Source Type: research
